Guangdong Taienkang Pharmaceutical Co., Ltd., a well-known brand in the health consumables industry, focuses on the development, manufacturing and sales of disinfection products/medical and sanitary consumables
Guangdong Taienkang Pharmaceutical Co., Ltd. (hereinafter referred to as "Taienkang") was established in 1999, with its registered address: Building 1, No. 48, Pujiang Road, Longhu District, Shantou City, and is a NEEQ listed company, stock code: 831173. Over the years, Taienkang has adhered to the corporate philosophy of "integrity, enterprising, and truth", adhered to the market-oriented, and is committed to selecting domestic and foreign characteristics and competitive pharmaceutical products for in-depth promotion and marketing. The company provides one-stop services from market demand analysis, marketing strategy planning to product sales, channel expansion to terminal management, customer relationship maintenance, etc., and has become a professional marketer of pharmaceutical products with marketing network as the core advantage and a high degree of marketization.
The company grasps the development trend of the pharmaceutical industry, prevents business risks, and continuously enhances its ability to control the market, and steadily improves its scale and efficiency. At present, Taienkang has formed a marketing network covering 30 provincial-level regions, more than 3,000 hospitals, thousands of distributors and nearly 20,000 terminal pharmacies. With a strong marketing network, rich industry experience, good industry reputation and long-term accumulation of pharmaceutical product marketing and promotion capabilities, the company has successfully marketed the "Hegao Rectal Pills" of Thailand Li Wanshan Pharmaceutical Factory (Diaoyu Trademark) Co., Ltd., the "Peppermint Surface Oil (Baoxinan Oil)" of Hong Kong Baoxinan Pharmaceutical Co., Ltd., the "Lecithin Complex Iodine Tablets (Volitin)" of Japan Daiichi Pharmaceutical Industry Co., Ltd., the "Xinsno" brand levonorgestrel dripping pills of Shandong Ruian Pharmaceutical Co., Ltd., and the medical devices of Johnson & Johnson of the United States At the same time, it also sells the self-produced "Wuhuan brand" characteristic external medicine series, "Tianfukang" brand series of oral preparations and "Taienkang" brand sanitary materials and diagnostic reagents and other medical devices. In the highly competitive economic environment of the pharmaceutical industry, we actively explore the innovation of marketing business models and achieve rapid development.
At present, the company has six wholly-owned subsidiaries - Guangdong Taienkang Pharmaceutical Factory Co., Ltd., Shantou Taienkang Medical Equipment Factory Co., Ltd., Shantou Taienkang Medical Equipment Co., Ltd., Guangdong Taienkang Technology Industrial Co., Ltd., Ma'anshan Tianfukang Pharmaceutical Co., Ltd., Guangzhou Taienkang E-commerce Co., Ltd., the industry covers the production of internal preparations, external preparations, medical consumables, Chinese medicine decoction pieces, traditional Chinese medicine pretreatment, and the marketing of domestic and foreign pharmaceutical products and medical devices; The company also gets involved in the pharmaceutical and cosmetics Internet through e-commerce companies, cooperates with the company's existing marketing, online and offline linkage operation, more comprehensively covers the company's customer groups, strives to build an innovative pharmaceutical operation platform, enhances the company's comprehensive profitability, and promotes the in-depth development of the Internet and the company's industrial integration.
Taienkang has made full use of the capital market to accelerate the improvement of the company's important layout of the integration of research, production and sales in the pharmaceutical industry. The company has joined hands with top scientists and senior review experts in the field of medicinal chemistry and pharmaceutical preparations at home and abroad to jointly establish Shandong Huabo Kaisheng Biotechnology Co., Ltd., which has become a subsidiary of Taienkang Holdings, effectively combining innovative technologies and laws and regulations, aiming to develop leading innovative drugs in China, including new anti-tumor drugs, and the main direction includes nanomicellar tumor targeted drugs, tumor immunotherapy drugs and other innovative products, marketing-oriented, based on the domestic reality. With a global vision and world-class technology development and integration capabilities, we continue to industrialize scientific research results, and the current research projects are of great market value. Since then, Taienkang has the R&D capabilities of leading innovative drugs in China.
In the future, with a sound marketing network, excellent and high-quality products, and a top R&D team, Taienkang will promote the construction of a comprehensive pharmaceutical enterprise with the whole industry chain of "research, production and sales", comprehensively enhance the company's market influence and profitability, continue to achieve rapid growth in performance, and maximize the win-win situation for customers, employees, society and shareholders!
